A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

417

Participants

Timeline

Start Date

June 26, 2006

Primary Completion Date

September 22, 2014

Study Completion Date

September 22, 2014

Conditions
Breast Cancer
Interventions
DRUG

Herceptin

8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly

DRUG

Docetaxel

75mg/m2 iv escalating to 100mg/m2 iv 3-weekly

DRUG

Pertuzumab

840mg iv loading dose, followed by 420mg iv 3-weekly

Trial Locations (77)

11

Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima

100

National Taiwan Uni Hospital; Dept of Oncology, Taipei

112

Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei

1090

Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Vienna

1100

Kaiser Franz Josef Spital; Iii. Medizinische Abt. Mit Onkologie, Vienna

3220

Geelong Hospital; Andrew Love Cancer Centre, Geelong

5154

Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica, Arequipa

5405

Kantonsspital Baden; Frauenklinik, Baden

6000

Mount Medical Center, Perth

8008

Brustzentrum, Zurich

10330

Chulalongkorn Hospital; Medical Oncology, Bangkok

10700

Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok

14004

Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba

17176

Karolinska Hospital; Oncology - Radiumhemmet, Stockholm

20025

ASST OVEST MILANESE; Oncologia Medica, Legnano

20132

Ospedale San Raffaele, Servizio di Oncologia e Chemioterapia, Milan

20133

Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milan

20230

Hospital Miguel Hidalgo, Aguascalientes

28007

Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid

28034

Hospital Ramon y Cajal; Servicio de Oncologia, Madrid

28046

Hospital Universitario La Paz; Servicio de Oncologia, Madrid

30035

Ospedale Calvi di Noale; U.O. Complessa di Oncologia ed Ematologia Oncologica, Mirano

33100

Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia, Udine

35340

Dokuz Eylul Uni Medical Faculty; Oncology Dept, Izmir

36014

Polo Ospedaliero Santorso, Santorso

36100

Ospedale Di Vicenza; Nefrologia, Oncologia Medica, Vicenza

40138

Az. Osp. S. Orsola Malpighi; Istituto Di Oncologia Seragnoli, Bologna

43100

Ospedale Regionale Di Parma; Divisione Di Oncologia Medica, Parma

46010

Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia

48903

Hospital de Cruces; Servicio de Oncologia, Barakaldo

50009

Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza

72530

Issstep Puebla, ; Oncology, Puebla City

75185

Akademiska sjukhuset, Onkologkliniken, Uppsala

90110

Prince of Songkla Uni ; Unit of Medical Oncology, Songkhla

115478

Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy, Moscow

129128

NSI of Healthcare Central Clinical Hospital #2 n.a. N.A.Semashko of the Russian Railways, Moscow

185007

State Institution Of Healthcare Republican Oncology Dispensary, Petrozavodsk

191104

SBI of Healthcare Leningrad Regional Oncology Dispensary, Saint Petersburg

197758

"FSBI Scientific Research Institute of Oncology named after N.N.Petrov Ministry of Health of RF", Saint Petersburg

354057

SI of HealthCare Oncologic Dispensary #2 of department of healthcare of Krasnodar region, Sashi

357502

State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary, Pyatigorsk

390011

"SBI for HPE Ryazan State Medical University n.a. I.P. Pavlov of MoH of RF", Ryazan

420111

SI of Healthcare Kazan Oncology Dispensary, Kazan'

443031

SBI of Healthcare Samara Regional Clinical Oncology Dispensary, Samara

4428164

Meir Medical Center; Oncology, Kfar Saba

6423906

Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv

98700-000

Hospital de Caridade de Ijui; Oncologia, Ijuí

91350-200

Hospital Nossa Senhora da Conceicao, Porto Alegre

88301-220

Clinica de Neoplasias Litoral, Itajaí

17210-080

Hospital Amaral Carvalho, Jaú

09060-650

Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia, Santo André

01221-020

Instituto do Cancer Arnaldo Vieira de Carvalho - ICAVC; Pesquisa Clinica, São Paulo

01317-000

Hospital Perola Byington, São Paulo

03102-002

Inst. Brasileiro de Controle Ao Cancer; Oncologia Clinica / Quimioterapia, São Paulo

18030-245

Instituto de Oncologia de Sorocaba - CEPOS, Sorocaba

E1C 6Z8

Moncton Hospital, Moncton

K7L 5P9

Cancer Centre of Southeastern Ontario; Kingston General Hospital, Kingston

M5G 2M9

University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto

H3G 1A4

McGill University; Montreal General Hosptial; Oncology, Montreal

G1S 4L8

CHU de Québec - Hôpital du Saint-Sacrement / ONCOLOGY, Québec

91120-01

Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem

06700

ARKE Estudios Clínicos S.A. de C.V., Mexico City

20-081

Samodzielny Publiczny Kliniczny Nr 1 W Lublinie; Klinika Chirurgii Onkologicznej, Lublin

20-090

COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej, Lublin

10-513

Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o., Olsztyn

60-569

Oddzial Chemioterapii Szpitala Klinicznego Nr 1 w Poznaniu, Poznan

61-485

NZOZ Centrum Medyczne HCP Sp. z o.o., Poznan

00-909

Central Hospital of Military School of Medicine; Oncology, Warsaw

02-781

Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii, Warsaw

ND

Ulyanovsk Regional Oncology Dispensary; Chemotherapy, Ulyanovsk

03080

Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology, Seoul

135-710

Samsung Medical Centre; Division of Hematology/Oncology, Seoul

08208

Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell

00112

VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei

06100

Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sıhhiye, Ankara

CV2 2DX

Walsgrave Hospital; Dept of Oncology, Coventry

M20 4QL

Christie Hospital; Breast Cancer Research Office, Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00545688 - A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. | Biotech Hunter | Biotech Hunter